ALEMBICLTDNSEAlembic Limited· PharmaceuticalsHighNeutral
Announced Thu, 12 Feb · 17:24 IST

Alembic Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.

Emphasis Of MatterResults View source PDF

ALEMBICLTD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Alembic Limited reported consolidated revenue from operations of ₹7,434 lakhs for Q3 FY26, up from ₹5,586 lakhs in the previous quarter and ₹5,792 lakhs in Q3 FY25. For the nine-month period, consolidated revenue grew about 11% to ₹17,995 lakhs (from ₹16,162 lakhs). Consolidated net profit (including share of associate Alembic Pharmaceuticals) for the nine months was ₹25,026 lakhs versus ₹24,223 lakhs last year, a modest ~3% rise, with EPS at ₹9.75 (vs ₹9.43). Standalone nine-month revenue rose ~12% to ₹17,420 lakhs, but standalone net profit dipped ~3.5% to ₹11,501 lakhs. The API business stood out with ~50% revenue growth in the nine-month period, while the real estate segment grew about 4%. The auditor included an Emphasis of Matter on a pending electricity duty dispute (₹2,052 lakhs principal provisioned, additional interest as contingent liability, and ₹35 crore already deposited with the Supreme Court). The company also booked an extra ₹143.72 lakhs provision for the newly notified Labour Codes.

Likely market impact

Results are mixed — top-line growth is healthy, especially in the API segment, but bottom-line growth is muted and standalone profits actually declined slightly. The ongoing electricity duty litigation remains a key overhang, though the auditor's opinion is unmodified. Expect a neutral-to-mildly positive market reaction, with focus on the strong API performance.